Pathologic response prediction of survival aided by tumor type

May 30, 2012
Pathologic response prediction of survival aided by tumor type

(HealthDay) -- Pathologic complete response (pCR) is more highly predictive of recurrence-free survival (RFS) when specific breast cancer tumor type is factored in, according to a study published online May 29 in the Journal of Clinical Oncology.

To investigate the association between pCR and RFS overall and within receptor subsets, Laura J. Esserman, M.D., from the University of California at San Francisco, and colleagues assessed clinical, imaging, and from 221 patients with a tumor of ≥3 cm (median, 6.0 cm) who had received neoadjuvant chemotherapy.

The researchers found that, based on a 70-gene prognosis profile, 91 percent of participants were classified as poor risk. Of the participants, 41 percent were hormone receptor (HR) negative and 31 percent were human epidermal growth factor receptor 2 (HER2) positive. Among the 190 patients not treated with neoadjuvant trastuzumab, pCR was highest for patients with HR-negative/HER2-positive tumors (45 percent) and lowest for patients with HR-positive/HER2-negative tumors (9 percent). Achieving pCR was predictive of improved RFS. For 172 patients treated without trastuzumab, patients with pCR had a hazard ratio of 0.29 for RFS when compared to patients with no pCR. On multivariate analysis, when subtype was factored in, pCR was more predictive of RFS, with lower hazard ratios for HR-positive/HER2-negative (hazard ratio, 0.00), HR-negative/HER2-negative (hazard ratio, 0.25), and HER2-positive (hazard ratio, 0.14) subtypes. The predictive value of pCR within subsets was further improved with Ki67.

"pCR is more highly predictive of RFS within every established receptor subset than overall, demonstrating that the extent of outcome advantage conferred by pCR is specific to tumor biology," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Explore further: Studies help clarify the role of lapatinib and trastuzumab in treating HER2 positive breast cancer

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Studies help clarify the role of lapatinib and trastuzumab in treating HER2 positive breast cancer

January 16, 2012
In patients with HER2-positive breast cancer, Tykerb (lapatinib) has been used both in combination with herceptin (trastuzumab) and as an alternative single-agent therapy for pre-surgery (neo-adjuvant) chemotherapy treatment. ...

Proteins do not predict outcome of herceptin treatment in HER2-positive breast cancer

December 9, 2011
Precisely quantifying the amount of three different HER growth proteins, along with several other proteins believed linked to breast cancer, did not predict a patient's outcome after treatment for HER2-Positive Breast Cancer ...

Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients

July 18, 2011
The use of trastuzumab, chemotherapy and surgery among women with HER2-positive metastatic breast cancer significantly improved survival from the time central nervous system metastases were diagnosed.

Early response is an indicator for rectal cancer survival

April 10, 2012
(HealthDay) -- In patients with locally advanced rectal cancer undergoing radical resection, response to neoadjuvant chemoradiotherapy is an early marker that correlates with rates of recurrence-free survival, distant metastases, ...

Recommended for you

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Dietary fat, changes in fat metabolism may promote prostate cancer metastasis

January 15, 2018
Prostate tumors tend to be what scientists call "indolent" - so slow-growing and self-contained that many affected men die with prostate cancer, not of it. But for the percentage of men whose prostate tumors metastasize, ...

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.